Map Key
Generic Enzyme
Generic kinase
Protein kinase
Lipid kinase
Generic phosphatase
Protein phosphatase
Lipid phosphatase
Generic phospholipase
Generic protease
Metalloprotease
G-alpha
RAS - superfamily
G beta/gamma
Regulators (GDI, GAP, GEF)
Generic channel
Ligand-gated channel
Voltage-gated channel
Transporter
Normal process
Pathological process
Positive effect
Negative effect
Unspecified effect
Technical link
Disrupts in disease
Emerges in disease
Enhances in disease
Weakens in disease
Organsim specific interaction

Generic binding protein
Receptor ligand
Cell membrane glycoprotein
Transcription factor
DNA
RNA
Compound
Inorganic ion
Predicted metabolite or user's structure
Reaction
Generic receptor
GPCR
Receptors with enzyme activity
Mitochondria
EPR
Golgi
Nucleus
Lysosome
Peroxisome
Cytoplasm
Extracellular

Normal process
Pathological process
Binding
Cleavage
Covalent modifications
Phosphorylation
Dephosphorylation
Transformation
Transport
Catalysis
Transcription regulation
MicroRNA binding
Competition
Influence on expression
Unspecified interactions
Pharmacological effect
Toxic effect
Group relation
Complex subunit
Similarity reaction
A complex or a group
Organism specific object

Development EDNRB signaling


Log In to Post A Comment

Development EDNRB signaling

EDNRB signaling

Endothelin receptor type B ( EDNRB ) belongs to the guanine nucleotide bindingprotein (G-protein) coupled receptor family. Endothelin-1 is most investigatedphysiological ligand of EDNRB [1]. EDNRB binds to many typesof the G-proteins but the main physiological consequence is exerted via its binding tothe G-protein alpha-q/11 and G-protein alpha-i family subunits [2], [3], [4].

Scaffolding Caveolin 1, caveolae protein, 22kDa ( Caveolin-1 ) interacts withEDNRB. EDNRB bound to Caveolin-1 is targeted to caveolae. UponEndothelin-1 stimulation, EDNRB dissociates from Caveolin-1 andexits from the caveolae. Caveolae localization of EDNRB is one of the mechanismsto ensure the balance of EDNRB -mediated signal transduction [5].

ENDRB stimulation by Endothelin-1 ( and, possibly, Endothelin-3) significantly enhances activity of Nitric oxide synthase 3 ( eNOS )which catalyzes Nitric Oxide synthesis from L-arginine [6],[7]. The mechanism of Nitric Oxide production in this case includesthe following steps. Endothelin - stimulated ENDRB activates G-proteinbeta/gamma dissociation from complex with G-protein alpha-i family.G-protein beta/gamma activates Phosphatidylinositol 3 kinase (PI3K) ( mostprobably, Phosphoinositide-3-kinase, regulatory subunit 5 ( PI3K reg class IB(p101) ) and Phosphoinositide-3-kinase, catalytic, gamma polypeptide ( PI3K catclass IB (p110-gamma) ), which products of PtdIns(3,4,5)P3 fromPtdIns(4,5)P2. PtdIns(4,5)P2, in turn, recruits v-akt murine thymomaviral oncogene homolog 1 ( AKT(PKB) ), which activates eNOS byphosphorylation and thus enhances Nitric Oxide production. Enhanced Nitricoxide production during EDNRB stimulation results in smooth muscle andvascular relaxation [7]. Nitric Oxide, in turn, enhancesintracellular concentration of cGMP, most likely by activation of the Guanylatecyclase 1, soluble [6], [8]. Guanylate cyclase 1,soluble activity, in turn, can stimulate cGMP - dependent Protein kinaseG, which abrogates downstream Mitogen activate protein kinases 1 and 3 (ERK1/2 ) phosphorylation by unknown mechanism [8].

Endothelin-1 via EDNRB induces activation of the downstream MAP kinases,mainly ERK1/2. The exact mechanism which leads to ERK1/2 activation isunclear but probably involves several pathways [9].

The first pathway proceeds via a ctivation of the EDNRB by its ligands,leading to t ransformation of the G-protein alpha-q/11 which activatesPhospholipase C beta ( PLC beta) and leads to hydrolysis of Phosphatidylinositol4,5-bisphosphate ( Ptdins(4,5)P2 ) and production of Diacylglycerol ( DAG )and Inositol trisphosphate ( IP3 ) [10]. IP3 leads toCa('2+) cytosol mobilization. Ca('2+) cytosol and DAG can activatesome RAP1A, member of RAS oncogene family ( RAP-1A ) activating factor (e.g., RASguanyl releasing protein 2 ( CALDAG-GEFI )) which transform RAP-1A toactive form. RAP-1A, in turn, activates effector - the v-raf murine sarcoma viraloncogene homolog B1 ( B-Raf ) [9]. DAG, probably, activatesProtein kinase C epsilon ( PKC-epsilon)/ v-Ha-ras Harvey rat sarcoma viraloncogene homolog ( H-Ras)/ v-raf-1 murine leukemia viral oncogene homolog 1 (c-Raf-1 ) pathway [9], [11].

The second pathway involves G-proteins alpha-i family [12] and,possibly, G-proteins beta/gamma [13], which activate cellular oncogenec-Src, which activates protein adaptor Shc/ Growth factor receptor bound2 ( GRB2 )/ Son of sevenless homolog ( SOS)/ H-Ras/c-Raf-1 pathway [12], [14].

Both pathways are merged downstream of B-Raf and c-Raf-1. B-Rafand/or c-Raf-1 phosphorylate and activate Mitogen-activated protein kinase kinases1 and 2 ( MEK1(MAP2K1) and MEK2(MAP2K2) ), which phosphorylate its maindownstream effectors ERK1/2 [9].

ERK1/2 may induce activation of the Ribosomal protein S6 kinase 90kDapolypeptide 2 and 3 ( p90RSK2 and p90RSK3 ). Most probably, ERK1/2activation results in phosphorylation of the ELK1, member of ETS oncogene family (Elk-1 ). In turn, p90RSK s activation results in phosphorylation of cAMPresponsive element binding protein 1 ( CREB1 ) and Activating transcription factor1 ( ATF-1 ). Transcriptional activity of the Elk-1, ATF-1 andCREB1 in this case may induce cellular oncogene v-fos FBJ murine osteosarcomaviral oncogene homolog ( c-Fos ) expression [9].

Proliferation, cell migration and contraction is a physiological consequences of theERK1/2 stimulation [15], [16], [17].